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Introduction
Traumatic and spontaneous intracranial bleeding are leading 
causes of death and disability worldwide. Traumatic brain injury, 
responsible for over 10 million deaths or hospitalisations each 
year1, is often accompanied by intracranial bleeding and the 
larger the bleed the worse the outcome2. Bleeding continues after 
hospital admission in most patients with moderate or severe 
traumatic brain injuries3. Haemorrhagic stroke affects about six 
million people every year worldwide4. About three million die and 
many survivors are permanently disabled4. Once again, bleeding 
can continue for up to 24 hours after stroke onset, although 
is most common in the first few hours5. The continuation of 
bleeding in the hours after onset in both traumatic and spontane-
ous intracranial bleeding, offers a therapeutic window to reduce 
the extent of the bleeding and improve patient outcomes.
Anti-fibrinolytics reduce bleeding by inhibiting the enzymatic 
breakdown of fibrin blood clots. They reduce surgical bleeding 
by about one third, irrespective of the site of surgery6,7. When 
given within three hours of onset, the anti-fibrinolytic tranexamic 
acid (TXA) reduces death due to bleeding in trauma and postpar-
tum haemorrhage, with no evidence of heterogeneity by type of 
bleeding8. However, in both trauma and postpartum haemor-
rhage there is no apparent benefit when treatment starts more than 
three hours after bleeding onset. TXA does not appear to increase 
the risk of thromboembolic events in extracranial bleeding7–9.
The improved outcomes with anti-fibrinolytic treatment in 
extracranial bleeding raises the possibility that they might improve 
outcomes after intracranial bleeding. There have been two 
small trials of TXA in traumatic brain injury10,11; both recruited 
patients within eight hours of injury. A meta-analysis showed 
a significant reduction in haemorrhage expansion with TXA12. 
However, even when combined the trials are too small to deter-
mine the overall risks and benefits, and whether these vary with 
treatment delay. Larger trials are ongoing. Trials of TXA in 
aneurysmal subarachnoid haemorrhage show less re-bleeding 
but more ischemia13. However, the long courses of treatment 
in these trials, unlike the eight-hour courses used in extracranial 
bleeding, may account for the increase in ischaemia. Larger trials 
of shorter regimens are underway14,15.
The Anti-fibrinolytics Trialists Collaboration (ATC) aims to 
increase knowledge about the effectiveness and safety of anti- 
fibrinolytic treatment by conducting individual patient data (IPD) 
meta-analyses of randomised trials of anti-fibrinolytics in acute 
severe bleeding involving 500 patients or more. This article 
presents the statistical analysis plan for an IPD meta-analysis of 
the effects of anti-fibrinolytics in acute intracranial haemorrhage. 
We are currently aware of four trials of TXA in patients with 
intracranial haemorrhage that meet the inclusion criteria for the 
IPD, the CRASH-3, TICH-2, ROC TXA and ULTRA clinical 
trials14–17. The lead investigators of the CRASH-3 and TICH-2 
trials are members of the ATC and co-authors of this statistical 
analysis plan. The lead investigators of the ROC TXA and ULTRA 
trial will also be invited to join the ATC and submit IPD for 
analysis. Versions 1 and 2 of this plan were prepared prior to 
knowledge of the results of any of these trials. However, revi-
sions for the preparation of version 3 were made after the results 
of the TICH-2 and ROC TXA trials were publically available.
Methods
Identification of eligible trials
We will conduct an individual patient data meta-analysis of 
randomised controlled trials with 500 patients or more that 
assessed the effects of anti-fibrinolytics (aprotinin, tranexamic 
acid, epsilon-aminocaproic acid and p-aminomethylbenzoic acid) 
in acute intracranial haemorrhage. To be included, a randomised 
trial must: i) be prospectively registered (i.e. before the first par-
ticipant is enrolled) in a trial registry; ii) randomise 500 patients 
or more; iii) be judged to be at low risk of bias for sequence 
generation, allocation concealment and blinding of outcome 
assessment. We will identify trials from a register of anti- 
fibrinolytic trials maintained by the LSHTM Clinical Trials Unit. 
Records included in this register are identified by running regu-
lar  searches of the following databases: MEDLINE, EMBASE, 
the Cochrane Central Register of Controlled Trials (CENTRAL), 
Database of Research in Stroke (DORIS), Web of Science, 
PubMed, Popline and the WHO International Clinical Trials 
Registry Platform. We will screen abstracts for relevant trials 
and apply the relevant selection criteria. We discuss reasons 
for exclusion and resolve discrepancies by consensus. Two 
reviewers will extract data to minimise bias. We will extract and 
describe data on patients and interventions for all trials irrespec-
tive of sample size. However, only IPD from trials involving 
500 patients or more will be sought and included in the analy-
sis to minimise small study effects. We will analyse individual 
            Amendments from Version 2
1.    Since the publication of the previous version of the article, 
the ATC has amended the inclusion criteria including 
lowering the sample size criterion from trials randomising 
1000 patients or more to trials randomising 500 patients or 
more. These amendments mean that two additional trials 
are now eligible for inclusion in this analysis, both of which 
we refer to in the revised manuscript.
2.    The Prospero record cited in the previous version has 
been superseded. We refer to the latest record in the 
revised manuscript.
3.    We have clarified that death assessed in the primary 
outcome will be limited to death due to head injury or 
stroke. This was specified in the protocol registration 
record but had been omitted in the earlier version of this 
manuscript.
4.    The two primary outcomes are not being formally analysed 
as co-primary outcomes, therefore we have removed the 
term ‘co-primary’.
5.    Accumulating knowledge of the effects of TXA, suggests 
that most of the benefit of TXA on risk of death may be 
limited to early deaths. For this reason we have added 
‘death within seven days of randomisation’ as a secondary 
outcome.
6.    We have identified ‘total volume of intracranial bleeding’ as 
the key neuro-radiological outcome.
7.    We have updated the number of patients included in the 
CRASH-3 trial neuro-radiological substudy to 1750.
See referee reports
UPDATE
Page 3 of 11
Wellcome Open Research 2019, 2:120 Last updated: 19 JUN 2019
patient data for baseline, outcome, and predictor variables; 
dates and times of randomisation and death. We registered the 
protocol in November 2016 (CRD42016052155) without any 
knowledge of the results of the large ongoing trials. The reg-
istration record has since been superseded by a new record 
registered in April 2019 (CRD42019128260) which reflects revi-
sions to the inclusion criteria. We judge that separate institu-
tional review board (IRB) approval for this study is not required. 
This project involves the analysis of existing trial data. Each 
trial providing individual patient data will have received local 
ethical approval. The planned study will not require further 
recruitment or data collection from patients and the analysis 
will not include identifiable data. The lead investigators of the 
CRASH-3 and TICH-2 trials agree that use of the IPD data from 
their trials does not require separate ethics committee approval. 
If, however, there is uncertainty about the use of data from other 
eligible trials, we will seek approval from the IRB board that 
originally approved the trial before including the data in the 
analysis.
Comparison of baseline measures between trials
Before conducting analyses to estimate the effects of anti- 
fibrinolytic treatment, we will present descriptive analyses to 
show any differences in baseline characteristics between the 
types of patient enrolled in the included trials. We will present 
statistical comparisons of baseline means (t-tests) and prevalence 
measures (chi-squared tests) for patients enrolled in the included 
trials.
Intention to treat analyses and missing data
We aim to include all randomised patients, regardless of whether 
they received the trial treatment, on an intention-to-treat basis. 
For patients who withdraw consent after randomisation, data 
collected up to the point of withdrawal will be included. We do 
not anticipate substantial amounts of missing data for the primary 
outcomes and subgroup factors. However, in the event that missing 
data is significant we will use a range of statistical approaches and 
will assess the impact of missing data on the results by conduct-
ing sensitivity analyses. We do anticipate substantial missing data 
for neuro-radiological outcomes measures, since many patients 
will not be scanned before and/or after randomisation because 
they died or did not require re-scanning. Indeed, the pilot data 
from the CRASH-3 Intracranial Bleeding Mechanistic Sub-study 
suggests that post-randomisation scans are less likely to be done 
in patients who die soon after admission (i.e. patients with a low 
Glasgow Coma Scale score) but also in patients who have a mild 
head injury (i.e. patients with a high Glasgow Coma Scale score) 
who do not need a second scan. We will report the number of 
patients without pre- and post-randomisation scans by treatment 
arm. If the outcome of interest (haemorrhage expansion) is asso-
ciated with the reason the data are missing (for example, patients 
with haemorrhage expansion may be more likely to die before 
the second scan), imbalance in missing data by treatment group 
could cause bias. If we suspect data are missing not at random, we 
will assess the impact of this in sensitivity analysis.
Primary outcomes
There are two primary outcomes.
1) Death from stroke or head injury within 30 days of randomi-
sation among patients treated within three hours of injury or 
stroke onset.
2) Death from stroke or head injury, or dependency at final 
follow-up within 90 days of randomisation among patients treated 
within three hours of injury or stroke onset. 
The eligible trials identified to date use the modified Rankin 
scale or Disability Rating scale to assess dependency. Depend-
ency will be defined as a score of 4–6 on the modified Rankin 
scale or a score of ≥12 on the Disability Rating Scale.
Although some trials recruit patients up to eight hours after 
injury or stroke onset, evidence from pathophysiological studies 
and trials of TXA in extra-cranial bleeding strongly suggest that 
treatment beyond three hours of onset is unlikely to improve 
outcomes. We believe that this is even more likely in the context 
of intracranial bleeding because the majority of bleeding occurs 
within the first few hours of injury18. We will examine the effects 
of anti-fibrinolytics on death using logistic regression. We will 
report treatment effects using odds ratios (OR) and 95% confi-
dence intervals (95% CI). We will first assess the homogeneity of 
the treatment effects between trials by estimating a random effects 
model where both the intercept and the treatment effect will be 
allowed to have a distribution across trials. The variance of the 
distribution of the treatment effect will give us an idea of the 
heterogeneity between trials. However, if only very few trials are 
included in the meta-analysis, instead of a random effects model 
we will examine the heterogeneity by including an interaction 
term between the treatment and the trial variable and reporting 
the p-value.
We will also plot a Kaplan-Meier curve for survival analysis 
comparing outcome of patients in treatment and placebo arms.
Subgroup analyses for primary outcomes
(a) Time to treatment – Does treatment delay modify the pro-
portional effect of anti-fibrinolytics on death and or dependency 
taking into account any other independent relationships between 
severity/age and the treatment effect?
We define treatment delay as the time from injury or symptom 
onset to randomisation. We appreciate that there will be some 
time interval between randomisation and treatment delivery 
but not all trials record the time of treatment delivery and we 
expect this interval to be short (0–15 minutes). We expect that 
the effect of TXA will vary by time to treatment with early 
treatment being most effective. Initially, we will plot treatment 
effects and 95% confidence intervals by 60-minute intervals of 
treatment delay. In addition, we will assess the impact of treat-
ment delay on treatment effect in a regression analysis that 
includes terms for hours of treatment delay and its square 
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(because of potential non-linearity of the treatment effect), and 
interactions between these two variables with treatment group. 
To explore the interaction between treatment effect and time, 
we will use the data on all treated patients and not only those 
treated within three hours.
We will check for potential heterogeneity of these effects 
across trials, by running a random effects models allowing the 
coefficients to vary randomly across trials. However, if we only 
include a small number of trials, instead of the random effects 
model we will include a triple interaction between the terms for 
treatment delay, the treatment group, and the trial.
Because severity of intracranial bleeding and age could con-
found impact of treatment delay on treatment effectiveness, we 
will control all models for GCS and age (10-year intervals) 
which are strong risk factors for death. If the above regression 
analyses indicate a trend towards decreasing treatment effective-
ness with increasing delay, we will estimate the time at which 
the estimated odds ratio reaches the null (1.00) and the time at 
which the lower 95% confidence interval reaches the null.
Because there is strong prior evidence to expect a time to 
treatment interaction, two-way interaction tests will be regarded 
as statistically significant and thus providing evidence of effect 
modification if the two-sided P-value is less than 0.05.
Assessment of regression dilution bias: Because time of 
bleeding onset (i.e. time of injury or stroke onset) is often 
uncertain, measurement error is inevitable. We will investigate 
the impact of misclassification of treatment delay in sensitivity 
analyses using a range of plausible errors. We will add a random 
number of minutes to the treatment delay using a uniform distri-
bution with a constant minimum set at 0 and four sets of maxi-
mum value: 15, 30, 45 and 60 minutes. The corrections are based 
on data from an audit of treatment delay in a large clinical trial 
in traumatic brain injury (the CRASH-3 trial) in which treatment 
delay was rarely over-estimated but often under-estimated 
(mean under-estimation 51 minutes). For each of the four maxi-
mum values, we will re-estimate the final model 100 times to 
obtain ranges for the time to treatment interaction.
(b) Severity of intracranial bleeding – Does severity modify the 
proportional effect of anti-fibrinolytics taking into account any 
other independent relationships treatment delay or age and 
treatment effect?
We will examine the effect of anti-fibrinolytics stratified by base-
line severity. All the eligible trials identified to date record GCS 
at baseline. We will examine three subgroups based on base-
line GCS: mild (GCS 13-15), moderate (GCS 9-12) and severe 
(GCS 3-8). We will use interaction tests to see whether the 
effect of the treatment (if any) differs across these subgroups. 
We will also assess the impact of baseline severity on the treat-
ment effect in a regression analysis that includes continuous terms 
for severity and its square (because of potential non-linearity 
of the treatment effect). Because treatment delay and age could 
confound impact of severity on treatment effectiveness, we will 
control all models for treatment delay and age (10-year 
intervals) and their interaction with treatment. Unless there is strong 
evidence against the null hypothesis of homogeneity of effects 
(i.e. p<0.01) the overall odds ratio will be considered the most 
reliable guide to the approximate treatment effect in all patients.
(c) Age – Does the patient’s age modify the proportional effect 
of anti-fibrinolytics taking into account any other independent 
relationships with treatment delay or severity and the treatment 
effect?
We do not expect the proportional benefits of anti-fibrinolytics to 
reduce with increasing patient age. However, because traumatic 
and spontaneous intracranial bleeding are increasingly common 
in older patients, who are sometimes denied potentially effec-
tive treatments on the basis that there is insufficient evidence in 
older patients, it will be important to consider this question. We 
will therefore conduct regression analyses to assess the impact of 
age on the treatment effect in a regression analysis that includes 
continuous terms for age and its square (because of potential 
non-linearity of the treatment effect) and their interaction with 
treatment. Because treatment delay and severity could confound 
the effect of age on treatment effectiveness, we will control all 
models for treatment delay and severity and their interactions 
with treatment. Unless there is strong evidence against the null 
hypothesis of homogeneity (i.e. p<0.01), the overall odds ratio 
will be considered the most reliable guide to the approximate 
treatment effect in all patients.
Secondary outcomes
We will assess the effect of TXA on the following secondary 
outcomes in all patients, irrespective of time of treatment.
Clinical outcomes
•    Death within seven days of randomisation
•    Dependency score
•    Cause specific mortality
•    Vascular occlusive events (myocardial infarction, stroke, 
deep vein thrombosis, pulmonary embolism)
•    Seizures
Neuro-radiological outcomes
The key neuro-radiological outcome will be the total volume 
of intracranial bleeding after randomisation (adjusting for total 
volume of intracranial bleeding at baseline if baseline volume is 
available).
Other neuro-radiological outcomes will be;
•    New focal ischaemic lesions (ischaemic lesions which 
appear on a post-randomisation scan but not known to be 
present pre-randomisation scan)
•    Frequency of progressive haemorrhage (number of patients 
with a post-randomisation CT scan with total haemor-
rhage volume of more than 33% of the volume on the pre- 
randomisation scan)
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•    The total volume of intracranial bleeding after neurosur-
gery (accounting for total volume of intracranial bleeding at 
baseline if baseline volume is available)
A selection of approximately 1750 patients in the CRASH-3 
trial are included in a neuro-radiological sub-study in which a 
simple validated rating scale (ABC/2) is used to measure intracra-
nial haemorrhage.  All patients in the TICH-2 trial undergo brain 
imaging before and the majority do so again after randomisation. 
Patients in the ROC TXA trial undergo CT scans if clinically 
indicated. Both the TICH-2 and ROC TXA trials also use the 
ABC/2 method to estimate intracranial haemorrhage.
Subgroup analysis of neuro-radiological outcome
We will conduct subgroup analysis to examine whether the 
effect of TXA on the key neuro-radiological outcome of total 
volume of intracranial bleeding after randomisation varies by 
haematoma type (intra-parenchymal, intra-ventricular, epidural, 
subdural, subarachnoid, lobar, deep). Intra-parenchymal haem-
orrhage is at the greatest risk of expansion and we hypothesise 
that TXA will be most likely to reduce bleeding of this type. 
Intra-ventricular haemorrhage and clots could block the flow of 
cerebrospinal fluid and thereby increase the risk of hydrocepha-
lus. TXA therefore may be ineffective or even harmful for patients 
with this type of bleeding. We will use interaction tests to see 
whether the effect of TXA (if any) differs across these subgroups. 
Unless there is strong evidence against the null hypothesis of 
homogeneity of effects (i.e. p<0.001) the overall relative risk 
will be considered the most reliable guide to the approximate 
relative risks in all subgroups.
Analyses will be conducted using STATA® (StataCorp, College 
Station, Texas, USA) statistical software.
Conclusions
The results of this IPD meta-analysis will provide a better 
understanding of the balance of risk and benefits of anti- 
fibrinolytic treatment in patients with intracranial haemorrhage 
and how they vary by time to treatment. This knowledge will 
enable better targeting of the use of anti-fibrinolytics and will 
influence treatment protocols.
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Thank you for bringing this new article to our attention. We have gone through the















We agree.  We will include a description of trials involving <1000 patients. We have







We agree with the reviewer.  For our first co-primary outcome we have specified death in
hospital within 30 days.  However, as the TICH-2 trial does not collect disability data
before 90 days, the second co-primary outcome is death in hospital or dependency at
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We confirm that the TICH-2 trial collects data on GCS pre-randomisation.  We have added
 a sentence to the relevant section in the Methods to clarify this.
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